New views on the treatment of uterine leiomyoma in women of reproductive age

Authors

  • А. Г. Корнацька SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Ukraine https://orcid.org/0000-0001-6638-6426
  • О. О. Ревенько SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Ukraine https://orcid.org/0000-0002-5784-3477
  • І. С. Колесніченко SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Ukraine
  • М. А. Флаксемберг Vinnitsa National Medical University named after M.I. Pirogov, Ukraine
  • Г. Ю. Обухова SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2017.36.82-85

Keywords:

uterine leiomyoma, infertility, combined therapy

Abstract

Uterine leiomyoma is the most common reproductive system disease in women of fertile age, which takes the leading place in frequency among tumors of the female sexual sphere. It is diagnosed in 20–70% of women of reproductive age. The uterine leiomyoma is still often treated surgically, and is the most common cause of hysterectomies.

The article examines the issues of increasing the effectiveness of treatment of uterine leiomyoma and its complications in women of reproductive age by using combined methods of conservative treatment. The results of examination and treatment of 55 patients aged 27–45 with different forms of leiomyoma are presented: intramural nodes (18–32.7%), intramuralsubserous (21–38.3%) and intramural-submucous (16–29.0%). The size of the dominant node varied from 4.5 to 12 cm. Clinical manifestations of leiomyoma was hyperpolimenorrhea (82.3%), lower abdominal pain (34.7%), frequent urination (15%). Also, 86% of women suffered from a decrease in hemoglobin in the blood.

In respect of all patients, organ-preserving surgical treatment was planned in connection with the desire of women to giving birth to a child. Patients took ulipristal acetate in a continuous regimen of 5 mg per day and indole-3-carbinol with epigallocatechin-3-gallate 1 tablet 2 times a day for 12 weeks. Women with anemia concurrently with this basic therapy took iron preparations inside.

43 (78.3%) women had amenorrhea since the beginning of treatment within a month. The mean decrease in the size of the uterus was 40.7%. After the end of treatment, 49 (89.0%) patients successfully underwent conservative myomectomy, and in 6 (11.0%) patients after the termination of treatment surgical intervention was avoided. During the year after the termination of the course of treatment 13 women became pregnant.

In using the combination therapy with ulipristal acetate in combination with indole-3-carbinol and epigallocatechin-3-gallate for 3 months the hemoglobin level was normalized, and the size of the leiomyoma was decreased, which is important for the safe operation. This therapy is a method of choice for the treatment of young women, who intend to exercise their reproductive function.

Author Biographies

А. Г. Корнацька, SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”

MD, professor, head of the Women Reproductive Function Rehabilitation Department

О. О. Ревенько, SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”

MD, chief researcher at the Department of Rehabilitation of the Women Reproductive Function

І. С. Колесніченко, SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”

Obstetrician gynecologist at the Department of Rehabilitation of the Women Reproductive Function

М. А. Флаксемберг, Vinnitsa National Medical University named after M.I. Pirogov

Assistant of Postgraduate Education Department

Г. Ю. Обухова, SI “Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”

Obstetrician gynecologist at the Department of Rehabilitation of the Women Reproductive Function

References

  1. Vdovichenko, Y.P., Ledin, D.S. “Infertility in women with uterine leiomyoma.” Pediatrics, obstetrics and gynecology 6 (2005): 89–93.
  2. Veropotvelyan, P.M., Veropotvelyan, M.P., Horuk, P.S., Kucher, N.M. “Uterine myoma – modern views on etiopathogenesis and methods of treatment.” Pediatrics, obstetrics and gynecology 2 (2010): 83–91.
  3. Ivaniuta, S.O., Ivaniuta, L.I. “Discussion issues of endosurgery in women of reproductive age.” Woman health 6 (2010): 55–7.
  4. Osinovskaya, N.S., Ivashchenko, Т.Е., Dzhemlikhanova, L.H., et al. “Peculiarities of estrogen and progesterone receptors polymorphism in women with uterine myoma.” Journal of Obstetrics and Women’s Diseases Vol. 51 Issue 3 (2012): 109–14.
  5. Savelyeva, T.M., Kurtsev, M.A., Brausenko, V.G., et al. “Endoscopic myomectomy: for and against.” Questions of gynecology, obstetrics and perinatology 6.1 (2007): 57–60.
  6. Description of the drug Epigalin®.
  7. Fernandez, H. “Update of myoma management – introduction.” J Gynecol Obstet Biol Reprod (Paris) 40.8 (2011): 856.
  8. Mara, M., Fucikova, Z., Maskova, J., et al. “Uterine fibroid embolization versus myomectomy in women wishing to preserve fertility: preliminary results of a randomized controlled trial.” Eur J Obstet Gynecol Reprod Biol 126.2 (2006): 226–33.

Downloads

Published

2017-09-14

How to Cite

Корнацька, А. Г., Ревенько, О. О., Колесніченко, І. С., Флаксемберг, М. А., & Обухова, Г. Ю. (2017). New views on the treatment of uterine leiomyoma in women of reproductive age. REPRODUCTIVE ENDOCRINOLOGY, (36), 82–85. https://doi.org/10.18370/2309-4117.2017.36.82-85

Issue

No. 36 (2017)

Section

Tumors and pretumoral pathology

License

Copyright (c) 2017 А. Г. Корнацька, О. О. Ревенько, І. С. Колесніченко, М. А. Флаксемберг, Г. Ю. Обухова

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.